Cross Cancer Institute ( Site 0010)

Edmonton, Alberta T6G 1Z2

0 studies enrolling now · 1 studies all time

What they study most

Esophageal Adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC)

Studies at this site

• Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) — Completed